Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Q4 2022 vs. Q3 2022
How the institutions holding Lakefront Biotherapeutics NV changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 84 | 1 | 75 | −8 |
| Shares | 12.9M | 4 | 13.2M | +255.5K (+2.0%) |
| Value | $551.1M | $0 | $584.8M | +$33.8M (+6.1%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Lakefront Biotherapeutics NV at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Stonepine Capital Management, LLC | 194,836 | $8.65M | 3.64% |
| BVF Inc | 100,000 | $4.44M | 0.19% |
| Suvretta Capital Management, LLC | 47,200 | $2.09M | 0.09% |
| Caption Management, LLC | 25,000 | $1.11M | 0.19% |
| Shay Capital LLC | 20,000 | $887.6K | 0.54% |
| Y-Intercept (Hong Kong) Ltd | 4,690 | $208.1K | 0.03% |
| Rockefeller Capital Management L.P. | 265 | $11.0K | 0.00% |
| WFA of San Diego, LLC | 200 | $8.88K | 0.01% |
| BNP Paribas Arbitrage, SA | 88 | $3.90K | 0.00% |
| Belpointe Asset Management LLC | 6 | $244 | 0.00% |
| Money Concepts Capital Corp | 2 | $89 | 0.00% |
| GWM Advisors LLC | 6 | $0 | 0.00% |
Sold out (20)
Institutions that held Lakefront Biotherapeutics NV at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Great Point Partners LLC | 306,411 | $13.1M |
| International Biotechnology Trust PLC | 123,300 | $5.25M |
| Jane Street Group, LLC | 66,424 | $2.83M |
| Endurant Capital Management LP | 50,822 | $2.17M |
| Alliancebernstein L.P. | 30,095 | $1.28M |
| New York Life Investments Alternatives | 28,584 | $1.22M |
| Marshall Wace, LLP | 17,149 | $732.0K |
| Trexquant Investment LP | 12,861 | $548.0K |
| Dimensional Fund Advisors LP | 11,755 | $501.0K |
| Gabelli Funds LLC | 8,700 | $452.0K |
| Aquatic Capital Management LLC | 8,200 | $350.0K |
| Balyasny Asset Management LLC | 8,147 | $347.0K |
| King Wealth | 8,000 | $341.0K |
| K2 Principal Fund, L.P. | 5,500 | $235.0K |
| FNY Investment Advisers, LLC | 3,000 | $127.0K |
| Leonteq Securities AG | 1,300 | $55.4K |
| CSS LLC | 599 | $26.0K |
| Atlas Capital Advisors LLC | 348 | $14.8K |
| SRS Capital Advisors, Inc. | 21 | $1.00K |
| Parallel Advisors, LLC | 35 | $1.00K |
Not filed for Q4 2022 yet (1)
Institutions that held Lakefront Biotherapeutics NV at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Wipfli Financial Advisors LLC, | 4 | $0 |